Advertisement

Congenital Factor V Deficiency

  • Shadi Tabibian
  • Akbar Dorgalaleh
  • Rodney M. Camire
Chapter

Abstract

Coagulation factor (F) V has a central role in the coagulation cascade. Following conversion to its active form (FVa), it functions as an essential cofactor in the prothrombinase complex, which accelerates the conversion of prothrombin to thrombin. In addition, this coagulation factor has anticoagulant activity, which acts as a cofactor for activated protein C (APC) for downregulation of FVIII. Congenital FV deficiency, also termed parahemophilia, is a rare bleeding disorder (RBD) with an estimated prevalence of 1 per million in the general population. This disorder most often presents in regions with a high rate of consanguineous marriages. The most common clinical manifestations of this disorder are mucosal and postsurgical bleeds, although life-threatening bleeding episodes are rare. FV deficiency is suspected through prolonged routine coagulation laboratory tests including prothrombin time (PT) and activate thromboplastin time (aPTT). The diagnosis is confirmed by specific diagnostic tests including FV antigen and activity assays. The only available therapeutic choice for patients with FV deficiency is fresh frozen plasma (FFP): the recommended dose is dependent on the location and severity of bleeding.

Keywords

Congenital factor V deficiency Rare bleeding disorder Diagnosis Management 

References

  1. 1.
    Mann KG, Kalafatis M. Factor V. A combination of Dr Jekyll and Mr Hyde. Blood. 2003;101(1):20–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Owren P. Parahaemophilia: haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;249(6449):446–8.CrossRefGoogle Scholar
  3. 3.
    Rosing J, Tans G, Govers-Riemslag J, Zwaal R, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 1980;255(1):274–83.PubMedGoogle Scholar
  4. 4.
    Shen L, Dahlbäck B, Factor V. protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem. 1994;269(29):18735–8.PubMedGoogle Scholar
  5. 5.
    Bolton-Maggs P, Perry D, Chalmers E, Parapia L, Wilde J, Williams M, et al. The rare coagulation disorders–review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia. 2004;10(5):593–628.CrossRefPubMedGoogle Scholar
  6. 6.
    Duckers C, Simioni P, Rosing J, Castoldi E. Advances in understanding the bleeding diathesis in factor V deficiency. Br J Haematol. 2009;146(1):17–26.CrossRefPubMedGoogle Scholar
  7. 7.
    Tabibian S, Kazemi A, Dorgalaleh A. Laboratory diagnosis of congenital factor V deficiency, routine, specific coagulation tests with molecular methods. J Cell Mol Anesth. 2016;1(2):87–90.Google Scholar
  8. 8.
    Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, Rosing J, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112(9):3615–23.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Favaloro EJ, Posen J, Ramakrishna R, Soltani S, McRae S, Just S, et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis. 2004;15(8):637–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Peyvandi F, Garagiola I, Biguzzi E. Advances in treatment of bleeding disorders. J Thromb Haemost. 2016;14(11):2095–106.CrossRefPubMedGoogle Scholar
  11. 11.
    Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry. 1992;31(15):3777–85.CrossRefPubMedGoogle Scholar
  12. 12.
    William H, Earl W. Blood coagulation factor V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood. 1988;71(71):539–55.Google Scholar
  13. 13.
    Ortel TL, Takahashi N, Putnam FW. Structural model of human ceruloplasmin based on internal triplication, hydrophilic/hydrophobic character, and secondary structure of domains. Proc Natl Acad Sci USA. 1984;81(15):4761–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Baumgartner S, Hofmann K, Bucher P, Chiquet-Ehrismann R. The discoidin domain family revisited: new members from prokaryotes and a homology-based fold prediction. Protein Sci. 1998;7(7):1626–31.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease. Arterioscler Thromb Vasc Biol. 2002;22(4):530–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature (Lond). 1999;402(6760):434.CrossRefGoogle Scholar
  17. 17.
    Villoutreix BO, Dahlbäck B. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Sci. 1998;7(6):1317–25.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lechtenberg BC, Murray-Rust TA, Johnson DJ, Adams TE, Krishnaswamy S, Camire RM, et al. Crystal structure of the prothrombinase complex from the venom of Pseudonaja textilis. Blood. 2013;122(16):2777–83.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Asselta R, Tenchini M, Duga S. Inherited defects of coagulation factor V: the hemorrhagic side. J Thromb Haemost. 2006;4(1):26–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Camire R, Bos M. The molecular basis of factor V and VIII procofactor activation. J Thromb Haemost. 2009;7(12):1951–61.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269(50):31869–80.PubMedGoogle Scholar
  22. 22.
    Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem. 1997;272(33):20678–83.CrossRefPubMedGoogle Scholar
  23. 23.
    Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999;93(8):2552–8.PubMedGoogle Scholar
  24. 24.
    Hockin M, Kalafatis M, Cawthern K, Simoni P, Mann K, editors. A novel cellular mechanism for factor Va inactivation. 40th Annual Meeting of the American Society of Hematology Blood; 1998.Google Scholar
  25. 25.
    Kalafatis M, Mann KG. The role of the membrane in the inactivation of factor va by plasmin. Amino acid region 307–348 of factor V plays a critical role in factor Va cofactor function. J Biol Chem. 2001;276(21):18614–23.CrossRefPubMedGoogle Scholar
  26. 26.
    Christella M, Thomassen L, Castoldi E, Tans G, Magdeleyns E, Delaunoit C, et al. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Haematologica. 2003;88(10):1150–6.Google Scholar
  27. 27.
    Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem. 2004;279(4):2383–93.CrossRefPubMedGoogle Scholar
  28. 28.
    Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem. 1995;270(35):20794–800.CrossRefPubMedGoogle Scholar
  29. 29.
    Lippi G, Favaloro EJ, Montagnana M, Manzato F, Guidi GC, Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis. 2011;22(3):160–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Naderi M, Tabibian S, Alizadeh S, Hosseini S, Zaker F, Bamedi T, et al. Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders. Acta Haematol. 2015;133(2):148–54.CrossRefPubMedGoogle Scholar
  31. 31.
    Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood. 2004;104(5):1243–52.CrossRefPubMedGoogle Scholar
  32. 32.
    Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol. 2015;8(4):527–42.CrossRefPubMedGoogle Scholar
  33. 33.
    Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009;35(4):382–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Acharya S, Coughlin A, Dimichele DM. Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost. 2004;2(2):248–56.CrossRefPubMedGoogle Scholar
  35. 35.
    Mansouritorghabeh H, Manavifar L, Mobalegh A, Shirdel A. Haemorrhagic manifestations and prevalence of factor V deficiency in North-Eastern Iran. Haemophilia. 2010;16(2):376–80.CrossRefPubMedGoogle Scholar
  36. 36.
    Lak M, Sharifian R, Peyvandi F, Mannucci F. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol. 1998;103:1067–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Thalji N, Camire RM. Parahemophilia: new insights into factor V deficiency. Semin Thromb Hemost. 2013;39(6):607–12.CrossRefPubMedGoogle Scholar
  38. 38.
    Peyvandi F, Palla R, Menegatti M, Siboni S, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615–21.CrossRefPubMedGoogle Scholar
  39. 39.
    Naderi M, Tabibian S, Shamsizadeh M, Dorgalaleh A. Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran. Int J Hematol. 2016;103(6):673–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Diamandis M, Adam F, Kahr W, Wang P, Chorneyko K, Arsenault A, et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost. 2006;4(5):1086–94.CrossRefPubMedGoogle Scholar
  41. 41.
    Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost. 2011;37(6):713–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Weiss HJ, Lages B, Zheng S, Hayward CP. Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation. Am J Hematol. 2001;66(2):130–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis. 2011;31(4):449–57.CrossRefPubMedGoogle Scholar
  44. 44.
    Miesbach W, Voigt J, Peetz D, Scharrer I. Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin. 2003;98(6):339–43.CrossRefGoogle Scholar
  45. 45.
    Lucia J, Aguilar C. A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia. 2005;11(2):178–80.CrossRefPubMedGoogle Scholar
  46. 46.
    Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y. Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis. 2003;14(1):87–93.CrossRefPubMedGoogle Scholar
  47. 47.
    Koyama T, Saito T, Kusano T, Hirosawa S. Factor V inhibitor associated with Sjögren’s syndrome. Br J Haematol. 1995;89(4):893–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002;42(1):18–26.CrossRefPubMedGoogle Scholar
  49. 49.
    Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001;233(1):88–96.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest. 1986;77(2):405.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ajzner E, Balogh I, Haramura G, Boda Z, Kalmar K, Pfliegler G, et al. Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost. 2003;1(5):943–9.CrossRefPubMedGoogle Scholar
  52. 52.
    Ortel TL, Moore KD, Quinn-Allen MA, Okamura T, Sinclair AJ, Lazarchick J, et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood. 1998;91(11):4188–96.PubMedGoogle Scholar
  53. 53.
    Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood. 2002;99(11):3985–92.CrossRefPubMedGoogle Scholar
  54. 54.
    de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol. 2003;74(3):187–90.CrossRefPubMedGoogle Scholar
  55. 55.
    Nuzzo F, Beshlawi I, Wali Y, Castoldi E. High incidence of intracranial bleeding in factor V-deficient patients with homozygous F5 splicing mutations. Br J Haematol. 2017;179(1):163–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Murray JM, Rand MD, Egan J, Murphy S, Kim H, Mann K. Factor V New Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood. 1995;86(5):1820–7.PubMedGoogle Scholar
  57. 57.
    Guasch J, Lensen R, Bertina R. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance. Thromb Haemost. 1997;77(2):252–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Vos H. An online database of mutations and polymorphisms in and around the coagulation factor V gene. J Thromb Haemost. 2007;5(1):185–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Castoldi E, Lunghi B, Mingozzi F, Muleo G, Redaelli R, Mariani G, et al. A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the Italian population. Haematologica. 2001;86(6):629–33.PubMedGoogle Scholar
  60. 60.
    Nuzzo F, Bulato C, Nielsen B, Lee K, Wielders S, Simioni P, et al. Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia. 2015;21(2):241–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Castoldi E, Bulato C, Nuzzo F, Nielsen B, Lee K, Key N, et al. Characterisation of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. J Thromb Haemost. 2013;11:195.CrossRefGoogle Scholar
  62. 62.
    Bain BJ, Bates I, Laffan MA. Dacie and Lewis practical haematology. Amsterdam: Elsevier; 2016.Google Scholar
  63. 63.
    Bloom JW, Nesheim ME, Mann KG. A rapid technique for the preparation of factor V deficient plasma. Thromb Res. 1979;15(5-6):595–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Tilley D, Levit I, Samis JA. Measurement of factor V activity in human plasma using a microplate coagulation assay. JoVE. 2012;67:3822.Google Scholar
  65. 65.
    Tilley D, Levit I, Samis JA. Development of a microplate coagulation assay for factor V in human plasma. Thromb J. 2011;9(1):11.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Favaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M, et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology. 2007;39(5):504–11.CrossRefPubMedGoogle Scholar
  67. 67.
    Favaloro EJ, Bonar R, Duncan E, Earl G, Low J, Aboud M, et al. Identification of factor inhibitors by diagnostic haemostasis laboratories. A large multi-centre evaluation. Thromb Haemost. 2006;96(1):73–8.PubMedGoogle Scholar
  68. 68.
    Knöbl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol. 1998;11(2):305–18.CrossRefPubMedGoogle Scholar
  69. 69.
    Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor-A problem-based systematic review. Thromb Haemost. 2009;101(5):852–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Salooja N, Martin P, Khair K, Liesner R, Hann I. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia. 2000;6(1):44–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology Am Soc Hematol Educ Program. 2016;2016(1):663–9.PubMedGoogle Scholar
  72. 72.
    Lawrie AS, Berbenni C, Menegatti M, Nardini I, Mackie I, Machin S, et al. In vitro characterizations of the first therapeutic factor V concentrate. Haemophilia. 2014;20:25–6.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Shadi Tabibian
    • 1
  • Akbar Dorgalaleh
    • 1
  • Rodney M. Camire
    • 2
  1. 1.Department of Hematology and Blood TransfusionSchool of Allied Medicine, Iran University of Medical SciencesTehranIran
  2. 2.Division of Hematology, Department of PediatricsChildren’s Hospital of Philadelphia, University of Pennsylvania, Perelman School of MedicinePhiladelphiaUSA

Personalised recommendations